The Puerto Rico House of Representatives approved a project that looks to set the foundations for a native pharmaceutical industry to reduce the impact of the exodus of foreign pharmaceutical companies.
The original version of this article is in Spanish. Read it by clicking on ESPAÑOL at the top right of your screen.
Neolpharma, a Mexican pharmaceutical group specializing in the production of generic medicines and contract manufacturing, opened operations yesterday in Caguas in a plant that used to be owned by Pfizer. The company might be a new business model for Puerto Rico, for the research and development market of "differentiated generics", a type of off-patent medicines that are more technically challenging to produce than regular generics. Neolpharma relocated to Puerto Rico, despite higher production costs, because of the talent pool of potential workers.